8:31AM Xenoport Submits Investigational new drug application for XP23829 as a potential treatment of RRMS (XNPT) 5.87 : Co announced that it has submitted an Investigational New Drug application to the FDA to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). Following clearance of the IND by the FDA, the first Phase 1 clinical trial to be conducted in healthy subjects will commence.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.